Phosphodiesterase type 5 inhibitor administered immediately after radical prostatectomy temporarily increases the need for incontinence pads, but improves final continence status

Yasuhiro Kaiho; Shinichi Yamashita; Akihiro Ito; Yoshihide Kawasaki; Hideaki Izumi; Naoki Kawamorita; Hisanobu Adachi; Koji Mitsuzuka; Yoichi Arai
September 2016
Investigative & Clinical Urology;Sep2016, Vol. 57 Issue 5, p357
Academic Journal
Purpose: To evaluate the effects of phosphodiesterase type 5 inhibitor (PDE5i) on urinary continence recovery after bilateral nerve-sparing radical prostatectomy (BNSRP). Materials and Methods: Between 2002 and 2012, 137 of 154 consecutive patients who underwent BNSRP in our institution retrospectively divided into 3 groups that included patients taking PDE5i immediately after surgery (immediate PDE5i group, n=41), patients starting PDE5i at an outpatient clinic after discharge (PDE5i group, n=56), and patients taking no medication (non-PDE5i group, n=40). Using self-administered questionnaires, the proportion of patients who did not require incontinence pads (pad-free patients) was calculated preoperatively and at 1, 3, 6, 12, 18, and 24 months after BNSRP. Severity of incontinence was determined based on the pad numbers and then compared among the 3 groups. Results: Proportions of pad-free patients and severity of incontinence initially deteriorated in all of the groups to the lowest values soon after undergoing BNSRP, with gradual improvement noted thereafter. The deterioration was most prominent in the immediate PDE5i group. As compared to the non-PDE5i group, both the PDE5i and immediate PDE5i groups exhibited a better final continence status. Conclusions: PDE5i improves final continence status. However, administration of PDE5i immediately after surgery causes a distinct temporary deterioration in urinary incontinence.


Related Articles

  • Preoperative erectile function is the only predictor of the use of a high number of phosphodiesterase type-5 inhibitors after bilateral nerve-sparing radical prostatectomy. Gandaglia, G; Gallina, A; Suardi, N; Abdollah, F; Passoni, N; Bianchi, M; Zaffuto, E; Nini, A; Vizziello, D; Salonia, A; Montorsi, F; Briganti, A // International Journal of Impotence Research;Nov/Dec2014, Vol. 26 Issue 6, p201 

    It is well known that the administration of phosphodiesterase type-5 inhibitors (PDE5-Is) may improve erectile function (EF) recovery after bilateral nerve-sparing radical prostatectomy (BNSRP). The aim of our study was to identify predictors of the use of a high number of PDE5-Is (one or more...

  • Current status of penile rehabilitation after radical prostatectomy. Jae Heon Kim; Seung Wook Lee // Korean Journal of Urology;Feb2015, Vol. 56 Issue 2, p99 

    Although disease-free survival remains the primary goal of prostate cancer treatment, erectile dysfunction (ED) remains a common complication that affects the quality of life. Even though several preventive and therapeutic strategies are available for ED after radical prostatectomy (RP), no...

  • Predictors of Urinary Continence Recovery after Modified Radical Prostatectomy for Clinically High-Risk Prostate Cancer. Guo-Liang Hou; Yun Luo; Jin-Ming Di; Li Lu; Yi Yang; Jun Pang; Jie Si-tu; Xin Gao // Urology Journal;Jan/Feb2015, Vol. 12 Issue 1, p2021 

    Purpose: To retrospectively determine predictors of urinary continence (UC) recovery in clinically high-risk prostate cancer (PCa) patients treated with modified radical prostatectomy (RP). Materials and Methods: A total of 184 patients with clinically high-risk PCa who underwent modified RP in...

  • Minimally invasive radical prostatectomy: Perception vs. Reality. Nirmal, T. J.; Kekre, N. S. // Indian Journal of Urology;Apr-Jun2010, Vol. 26 Issue 2, p318 

    This population-based observational cohort study assesses the outcomes of minimally invasive radical prostatectomy (MIRP) vs. open radical retropubic prostatectomy (RRP). Using the Surveillance, Epidemiology, and End Results (SEER)-Medicare data base, 8837 men aged 65 years or older, who...

  • PDE5 inhibitors: no increased risk of prostate cancer recurrence.  // Reactions Weekly;2/20/2016, Vol. 1589 Issue 1, p8 

    An abstract of the article "Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment" by S. Loeb and others is presented.

  • PDE5i increase risk of biochemical recurrence after prostatectomy.  // Reactions Weekly;Feb2015, Vol. 1538 Issue 1, p10 

    The article reports on a medical study which found that the use of phosphodiesterase type 5 inhibitors (PDE5i) after radical prostatectomy (RP) in patients with prostate cancer increases the risk of biochemical recurrence.

  • Role of preserving the bladder neck in urinary continence in patients with radical retropubic prostatectomy. Feciche, B.; Ona, V.; Rusu, C.; Gorbatai, L.; Botezan, T.; Salageanu, N. // Romanian Journal of Urology;2014, Vol. 13 Issue 1, p28 

    Introduction: Radical prostatectomy is the main therapeutic method applied to cure localized prostate cancer. This paper assesses the value of preserving the bladder neck within the preservation ofpostoperative continence in several patients operated on by means of radical retropubic...

  • The Diagnosis and Treatments of Inguinal Hernia after Radical Prostatectomy. Tao Li; Zhiping Wang // Surgical Science;Jan2013, Vol. 4 Issue 1, p83 

    Prostate cancer (PC) is one of the most common causes of cancer-related death in the world among old men. Radical prostatectomy (RP) is the most common surgical procedure in treatments. However, the complications after RRP always confuse surgeons. Urinary incontinence, impotence, erectile...

  • Oncological and functional outcomes of 722 robot-assisted radical prostatectomy (RARP) cases: The largest Canadian 5-year experience. Tholomier, Côme; Bienz, Marc; Hueber, Pierre-Alain; Trinh, Quoc Dien; Hakim, Assaad El; Alhathal, Naif; Lebeau, Thiery; Benayoun, Serge; Valdivieso, Roger; Liberman, Dan; Saad, Fred; Lattouf, Jean-Baptiste; Widmer, Hugues; Begin, Louis; Latour, Mathieu; Zorn, Kevin C. // Canadian Urological Association Journal;May/Jun2014, Vol. 8 Issue 5/6, p195 

    Introduction: While RARP (robotic-assisted radical prostatectomy) has become the predominant surgical approach to treat localized prostate cancer, there is little Canadian data on its oncological and functional outcomes. We describe the largest RARP experience in Canada. Methods: Data from 722...

  • Long-term complications in men who have early or late radiotherapy after radical prostatectomy. Sowerby, Robert J.; Gani, Johan; Yim, Harold; Radomski, Sidney B.; Catton, Charles // Canadian Urological Association Journal;jui/aou2014, Vol. 8 Issue 7/8, p253 

    Introduction: Choosing adjuvant radiotherapy (RT) or salvage RT after radical prostatectomy (RP) for locally advanced prostate cancer is controversial. Performing RT early after RP may increase the risk of urinary complications compared to RT performed later. We evaluated the urinary...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics